<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02688101</url>
  </required_header>
  <id_info>
    <org_study_id>CMD-2015-001</org_study_id>
    <nct_id>NCT02688101</nct_id>
  </id_info>
  <brief_title>Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Collaborative Medicinal Development Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Collaborative Medicinal Development Pty Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, open-label, dose-escalation and pharmacokinetic study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, open-label, phase 1 study of DpC administered orally to patients with advanced&#xD;
      solid tumors. The study will be conducted in two parts. In the first phase successive cohorts&#xD;
      of patients (3+3) will receive escalating doses of DpC until the maximum tolerated dose (MTD)&#xD;
      is reached. MTD is based on tolerability observed during the first 28 days of treatment. The&#xD;
      second part of the study involves treatment of expansion cohorts (10-15 patients each) in&#xD;
      specific indications to confirm the tolerability of treatment at the recommended phase 2 dose&#xD;
      and schedule and evaluate evidence of anti-tumor activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 11, 2016</start_date>
  <completion_date type="Actual">October 26, 2017</completion_date>
  <primary_completion_date type="Actual">October 26, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended phase 2 dose as determined by number of participants at each dose level with dose limiting toxicities</measure>
    <time_frame>36 months</time_frame>
    <description>Determine recommended phase 2 dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum DpC plasma concentration [Cmax] following dosing on Days 1 and 28 based on blood draws taken at 1, 2, 4, 8, and 24 hours after dosing</measure>
    <time_frame>30 months</time_frame>
    <description>Maximum DpC plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the DpC plasma concentration vs. time curve [AUC] following dosing on Days 1 and 28 based on blood draws taken at 1, 2, 4, 8, and 24 hours after dosing</measure>
    <time_frame>30 months</time_frame>
    <description>DpC area under the plasma concentration vs. time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with tumor responses as assessed by RECIST criteria</measure>
    <time_frame>36 months</time_frame>
    <description>number of tumor responses by RECIST criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>DpC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DpC capsules, administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DpC</intervention_name>
    <description>iron chelator</description>
    <arm_group_label>DpC</arm_group_label>
    <other_name>Dp4cycH4mT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent prior to initiation of any study-specific procedures;&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of an advanced or metastatic solid&#xD;
             tumor for which standard therapy either does not exist or has proven ineffective,&#xD;
             intolerable, or unacceptable for the patient;&#xD;
&#xD;
          -  At least one measurable lesion as defined by RECIST v1.1, except for patients with&#xD;
             castrate resistant prostate cancer, who may be enrolled with objective evidence of&#xD;
             disease per PCWG2 criteria, and patients with ovarian cancer who may be enrolled&#xD;
             without measurable disease but who are evaluable by CA125 per GCIC criteria;&#xD;
&#xD;
          -  life expectancy at least 3 months;&#xD;
&#xD;
          -  ECOG performance status 0-1;&#xD;
&#xD;
          -  Adequate bone marrow reserve, cardiac, renal and liver function, defined by&#xD;
&#xD;
          -  absolute neutrophil count at least 1.5 x 10(9)/L;&#xD;
&#xD;
          -  platelet count at least 100 x 10(9)/L;&#xD;
&#xD;
          -  hemoglobin at least 9 g/dL;&#xD;
&#xD;
          -  ferritin at least 50 ug/L;&#xD;
&#xD;
          -  ECHO shows ejection fraction at least 50% and no evidence of cardiac dysfunction;&#xD;
&#xD;
          -  creatinine clearance &gt;50 mL/min (Cockcroft &amp; Gault formula);&#xD;
&#xD;
          -  AST/ALT no more than 3 x ULN (5 x ULN if liver or bone involvement);&#xD;
&#xD;
          -  serum albumin at least 28 g/L;&#xD;
&#xD;
          -  INR no more than 1.5 x ULN;&#xD;
&#xD;
          -  At least 3 weeks since chemotherapy, immunotherapy, hormone therapy, r other&#xD;
             anticancer therapy or surgical intervention or at least 3 half-lie for monoclonal&#xD;
             antibodies;&#xD;
&#xD;
          -  Patients with castrate-resistant prostate cancer must maintain ongoing androgen&#xD;
             deprivation therapy to provide serum testosterone &lt;50 mg/dL;&#xD;
&#xD;
          -  Patients receiving bisphosphonate or denosumab therapy must be on stable doses for at&#xD;
             least 4 weeks before initiating study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to swallow oral medications or presence of a GI disorder deemed to&#xD;
             jeopardize intestinal absorption of DpC;&#xD;
&#xD;
          -  Persistent grade &gt;1 clinically significant toxicities related to prior anticancer&#xD;
             treatment (except alopecia);&#xD;
&#xD;
          -  Known primary CNS malignancy or CNS involvement (except for brain mets that have been&#xD;
             treated and are stable and patient is off steroids);&#xD;
&#xD;
          -  History of prior to concomitant malignancies (other than fully excised non-melanoma&#xD;
             skin cancer, cured in situ cervical carcinoma, early stage bladder cancer or DCIS of&#xD;
             breast) within 3 years of study entry;&#xD;
&#xD;
          -  History of atrial fibrillation or evidence of atrial enlargement on baseline ECHO;&#xD;
&#xD;
          -  History of hemoglobinopathy;&#xD;
&#xD;
          -  Current use of iron chelation therapy;&#xD;
&#xD;
          -  Other serious illness or medial condition;&#xD;
&#xD;
          -  Participation in another clinical trial or treatment with any investigational drug&#xD;
             within 30 days prior to study entry;&#xD;
&#xD;
          -  Current use of anticoagulants at therapeutic levels;&#xD;
&#xD;
          -  Pregnant or breast-feeding patients and men and women of child-bearing potential not&#xD;
             using effective contraception while on study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Mileshkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peter MacCallum Cancer Centre, Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lifehouse Cancer Treatment Centre</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olivia Newton John Cancer Centre</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Cancer Center</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>January 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2016</study_first_posted>
  <last_update_submitted>February 19, 2019</last_update_submitted>
  <last_update_submitted_qc>February 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

